In The News

May 2, 2022 Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting

Apr 25, 2022 Kazia Therapeutics establishes ‘at the market’ equity program

Apr 21, 2022 Kazia Therapeutics completes Phase 2 study of glioblastoma drug Paxalisib; data to follow at conference

Apr 8, 2022 Kazia Therapeutics encouraged by “promising data” on its cancer pipeline presented at AACR meeting in New Orleans

Feb 28, 2022 Kazia Therapeutics initiates Phase II study of paxalisib for newly diagnosed and recurrent glioblastoma

Feb 24, 2022 Kazia Therapeutics delivers on plans with two promising assets in human trials

Dec 12, 2021 Kazia Therapeutics appoints US-based CFO to assist global market expansion

Dec 9, 2021 Kazia Therapeutics' clinical paxalisib data maintains Speculative Buy rating from Bell Potter

Dec 3, 2021 ASX up, Berkshire billionaire gives his views on crypto and will BHP benefit from rising iron ore prices?

Dec 3, 2021 Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug